SOURCE: Hansen Medical, Inc.

Hansen Medical, Inc.

December 14, 2010 16:01 ET

Hansen Medical Names Rita Jacob Vice President for Training and Clinical Affairs

Significant Expertise in Training of Vascular Surgeons and Interventionalists, and Clinical Research on Class II and III Vascular Devices

MOUNTAIN VIEW, CA--(Marketwire - December 14, 2010) -  Hansen Medical, Inc. (NASDAQ: HNSN), a global leader in flexible robotics and the developer of robotic technology for accurate 3D control of catheter movement, today named industry veteran Rita V. Jacob Vice President for Training and Clinical Affairs, effective immediately. Jacob will report directly to President and CEO Bruce Barclay.

Jacob, 50, has more than 20 years of experience in training, technical support and clinical research in collaboration with both vascular surgeons and interventionalists. Most recently she was Director, Clinical Affairs, Vascular Therapies for San Jose, California based Covidien, which acquired her previous employer Bacchus Vascular, where she was Vice President, Clinical Affairs. Before Bacchus, Jacob helped design and manage training and clinical research of AAA (abdominal aortic aneurysm) stent grafts for both Medtronic and Boston Scientific. Earlier in her career she held multiple clinical sales and related positions with Guidant.

"Rita has a breadth of expertise working closely with physicians as the head of a global training effort, which is a capability we will draw on at Hansen," Barclay said. "Training of both our field based employees and the physicians and hospital staff using our products in electrophysiology and vascular is critical to our future success. Our planned entrance into the vascular market in the coming year is a key milestone, and effective training will be a cornerstone to a successful commercial launch. She has direct experience in the global vascular market, which is important as we move forward with the expected commercialization of our flexible catheter vascular robotic system in both the US and Europe. After commercial launch, designing and managing clinical research to generate relevant data for clinicians and payors alike will also be critical, and Rita has a long track record of success in this area as well."

"I'm impressed with both the technology and management team assembled to develop and commercialize this groundbreaking technology," Jacob said. "I believe the benefit of the vascular robotic system to the interventional physician and their patients could be significant. It is an honor to have been sought out for this challenging opportunity and I look forward to applying my experience in vascular and minimally invasive therapies to deliver positive results for Hansen Medical's stakeholders."

Jacob has a Bachelor of Science degree in nursing from the University of Maryland and is a registered nurse.

About Hansen Medical, Inc.
Hansen Medical, Inc., based in Mountain View, California, develops products and technology using robotics for the accurate positioning, manipulation and control of catheters and catheter-based technologies. The company's Sensei® system and its Sensei X Robotic Catheter System were cleared by the U.S. Food and Drug Administration for manipulation and control of certain mapping catheters in electrophysiology (EP) procedures. This robotic catheter system is compatible with fluoroscopy, ultrasound, 3D surface map and patient electrocardiogram data. In the United States, the Sensei System is not approved for use in guiding ablation procedures; this use remains experimental. The U.S. product labeling therefore provides that the safety and effectiveness of the Sensei and Sensei X systems for use with cardiac ablation catheters in the treatment of cardiac arrhythmias, including atrial fibrillation (AF), have not been established during EP procedures, such as guiding catheters in the treatment of AF. In the European Union, the Sensei and the Sensei X systems are cleared for use during EP procedures, such as guiding catheters in the treatment of AF. The vascular robotic system requires regulatory filings and approval and is not commercially available. Additional information can be found at www.hansenmedical.com.

Forward-Looking Statements
This press release contains forward-looking statements that involve risks, uncertainties, assumptions and other factors which, if they do not materialize or prove correct, could cause Hansen's results to differ materially from those expressed or implied by such forward-looking statements. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including statements containing the words "expected", "planned" and similar words. Hansen Medical intends such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 21E of the Exchange Act and the Private Securities Litigation Reform Act of 1995. Examples of such statements include statements about the expected timing of commercialization of our investigational vascular robotic system, expectations regarding data generated from any clinical research and the importance of training on the commercial launch. Important factors that could cause actual results to differ materially from those indicated by forward-looking statements include, among others, potential safety and regulatory issues that could delay, suspend or terminate clinical studies, regulatory approvals or sales, challenges in designing, engineering and manufacturing systems to function as intended, uncertain timelines, costs and results of clinical trials and development of new products, our ability to plan and manage cost-reduction or operational efficiency initiatives, the scope and validity of intellectual property rights applicable to products being developed, and our ability to remediate material weaknesses in internal controls over financial reporting. These and other risks are described in greater detail under the heading "Risk Factors" contained in our periodic SEC filings, including our Quarterly Report on Form 10-Q filed with the SEC on November 9, 2010. Given these uncertainties, you should not place undue reliance on the forward-looking statements in this press release. We undertake no obligation to revise or update information herein to reflect events or circumstances in the future, even if new information becomes available.

Hansen Medical, Heart Design, Hansen Medical & Heart Design, and Sensei are registered trademarks of Hansen Medical, Inc. in the United States and other countries. 

Contact Information

  • Investor Contacts:
    Peter Osborne
    Interim CFO
    Hansen Medical
    650.404.5800

    Matt Clawson
    Allen & Caron Inc
    949.474.4300
    Email Contact